1-苄基-4-苯基哌啶-4-甲醇 | 59083-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-苯基哌啶-4-甲醇
• 英文名称: 1-benzyl-4-(hydroxymethyl)-4-phenylpiperidine
• 英文别名: 1-benzyl-4-hydroxymethyl-4-phenylpiperidine；(1-benzyl-4-phenyl-piperidin-4-yl)-methanol；1-benzyl-4-phenylpiperidine-4-methanol；1-benzyl-4-hydroxymethyl-4-phenyl-piperidine；1-Benzyl-4-phenylpiperidin-4-methanol；(1-benzyl-4-phenylpiperidin-4-yl)methanol
• CAS: 59083-36-2
• 化学式: C₁₉H₂₃NO
• 分子量: 281.398
• InChiKey: BAWRMFFOXIGBQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-苄基-4-苯基哌啶-4-甲醇 在 chromium(VI) oxide 、 盐酸 作用下， 以 1,4-二氧六环 、 水 、 溶剂黄146 为溶剂， 反应 12.5h， 生成 1'-benzylspiro-1-one hydrochloride
  参考文献：
  名称：

  螺[异香豆素-哌啶]及相关化合物的合成及生物活性。一世。

  摘要：

  1'-烷基螺[异香豆素-3, 4'-哌啶]-1-酮（2）和1'-烷基螺[异香豆素-4, 4'-哌啶]（4和5）已经被合成并检查其镇痛活性。发现其中几种4-螺化合物（3、4和5）的镇痛活性与氨基吡嗪相当，而3-螺化合物（2）则无活性。进一步的药理研究表明，这些化合物中的几种抑制了由化合物48/80诱导的孤立大鼠腹膜肥大细胞释放组胺。

  DOI：

  10.1248/cpb.29.402
• 作为产物：
  描述：

  Methyl 1-benzyl-4-phenylpiperidine-4-carboxylate 生成 1-苄基-4-苯基哌啶-4-甲醇
  参考文献：
  名称：

  YAMATO, MASATOSI;TASAKA, KEHNDZI

  摘要：

  DOI：

文献信息

• 1-azoniabicyclo\x9b2.2.1!heptanes, method of preparing them and
  申请人：Sanofi

  公开号：US05679693A1

  公开（公告）日：1997-10-21

  The invention relates to quaternary basic amides of the formula ##STR1## in which Ar is an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group; T is a direct bond, a hydroxymethylene group, an alkoxymethylene group in which the alkoxy group is C.sub.1 -C.sub.4, or a C.sub.1 -C.sub.5 -alkylene group; Ar' is an unsubstituted or mono- or poly-substituted phenyl, a thienyl, a benzothienyl, a naphthyl or an indolyl; R is hydrogen or a C.sub.1 -C.sub.4 -alkyl, or a C.sub.1 -C.sub.4 -.omega.-alkoxy(C.sub.2 -C.sub.4)alkyl, or a C.sub.2 -C.sub.4 -.omega.-alkanoyloxy (C.sub.1 -C.sub.4)alkyl;. Q is hydrogen; or else Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4-butylene group; Am.sup..sym. is the radical ##STR2## in which X.sub.1, X.sub.2 and X.sub.3, together with the nitrogen atom to which they are bonded, form a 1-AZONIABICYCLO\x9b2.2.1!HEPTANE optionally substituted by a phenyl or benzyl group; and A.sup..crclbar. is a pharmaceutically acceptable anion. These compounds are useful for the preparation of drugs intended for the treatment of pathological conditions involving the tachykinin system.

  该发明涉及公式为##STR1##的四元碱性酰胺，其中Ar是一个可选择取代的单环、双环或三环芳香或杂芳基团；T是直链键，羟甲亚基，烷氧甲亚基，其中烷氧基是C.sub.1 -C.sub.4，或C.sub.1 -C.sub.5-烷基亚基；Ar'是未取代或单取代或多取代的苯基，噻吩基，苯噻吩基，萘基或吲哚基；R是氢或C.sub.1 -C.sub.4-烷基，或C.sub.1 -C.sub.4-ω-烷氧基(C.sub.2 -C.sub.4)烷基，或C.sub.2 -C.sub.4-ω-烷酰氧基(C.sub.1 -C.sub.4)烷基；Q是氢；或者Q和R一起形成1,2-乙烯，1,3-丙烯或1,4-丁烯基团；Am.sup..sym.是基团##STR2##其中X.sub.1、X.sub.2和X.sub.3与它们连接的氮原子一起形成一个1-AZONIABICYCLO\x9b2.2.1!HEPTANE，该环可选择由苯基或苄基取代；A.sup..crclbar.是一种药用可接受的阴离子。这些化合物可用于制备用于治疗涉及Tachykinin系统的病理条件的药物。
• Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogs for inhibition of histamine release. 1
  作者：Masatoshi Yamato、Kuniko Hashigaki、Masao Ikeda、Hidetoshi Ohtake、Kenji Tasaka

  DOI：10.1021/jm00134a013

  日期：1981.2

  ,4'-piperidines] were prepared and examined for their biological activity. Several of the compounds inhibited the compound 48/80 induced histamine release from isolated rat peritoneal mast cells. The structural requirements for this activity in the present series are discussed.

  制备了两种类型的1'-烷基螺基[isochroman-3,4-哌啶]和1'-烷基螺基[isochroman-4,4'-哌啶]并检查了它们的生物学活性。几种化合物抑制了化合物48/80诱导的组胺从分离的大鼠腹膜肥大细胞中释放。讨论了本系列中此活动的结构要求。
• 4,4-Disubstituted piperidines, and methods of use thereof
  申请人：Hoemann Z. Michael

  公开号：US20070225331A1

  公开（公告）日：2007-09-27

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的另一个方面涉及将这些杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、病症和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合症、睡眠障碍、注意力缺陷多动症、肠易激综合症、早泄、月经困扰综合症、尿失禁、炎症性疼痛、神经病性疼痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成这些杂环化合物的组合库，以及筛选这些库的生物活性，例如在基于多巴胺转运体的测定中。
• 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES
  申请人：Cid-Núñez José Maria

  公开号：US20100063092A1

  公开（公告）日：2010-03-11

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是根据公式（I）的新型吡啶酮衍生物，包括其任何立体化异构体形式、药学上可接受的盐或其溶剂化物，其中所有基团在申请和权利要求中均有定义。本发明所述化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。特别是，这些疾病是选择自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的一组。本发明还涉及制备这种化合物和这种组合物的制药组合物和过程，以及将这种化合物用于预防和治疗涉及mGluR2的这种疾病。
• YAMATO MASATOSHI; HASHIGAKI KUNIKO; IKEDA MASAO; ONTAKE HIDETOSHI; TASAKA+, J. MED. CHEM., 1981, 24, NO 2, 194-198
  作者：YAMATO MASATOSHI、 HASHIGAKI KUNIKO、 IKEDA MASAO、 ONTAKE HIDETOSHI、 TASAKA+

  DOI：——

  日期：——